Munagala Mrudula R, Phancao Anita
Department of Cardiology, Newark Beth Israel Medical Center, 201 Lyons Avenue, Suite # L4, Newark, NJ 07112, USA.
Integris Baptist Medical Center, 3400 Northwest Expressway, Building C, Suite 200, Oklahoma City, OK 73112, USA.
Med Clin North Am. 2016 May;100(3):519-33. doi: 10.1016/j.mcna.2016.01.004. Epub 2016 Mar 18.
Solid organ transplantation is an effective treatment for patients with end-stage organ disease. The prevalence of cardiovascular diseases (CVD) has increased in recipients. CVD remains a leading cause of mortality among recipients with functioning grafts. The pathophysiology of CVD recipients is a complex interplay between preexisting risk factors, metabolic sequelae of immunosuppressive agents, infection, and rejection. Risk modification must be weighed against the risk of mortality owing to rejection or infection. Aggressive risk stratification and modification before and after transplantation and tailoring immunosuppressive regimens are essential to prevent complications and improve short-term and long-term mortality and graft survival.
实体器官移植是终末期器官疾病患者的有效治疗方法。心血管疾病(CVD)在移植受者中的患病率有所增加。CVD仍然是移植功能良好的受者死亡的主要原因。CVD受者的病理生理学是既往存在的危险因素、免疫抑制剂的代谢后遗症、感染和排斥反应之间复杂的相互作用。必须在风险调整与因排斥反应或感染导致的死亡风险之间进行权衡。在移植前后进行积极的风险分层和调整,并调整免疫抑制方案,对于预防并发症、提高短期和长期死亡率以及移植物存活率至关重要。